Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Weiping Cao is active.

Publication


Featured researches published by Weiping Cao.


The Journal of Infectious Diseases | 2013

Protein Energy Malnutrition Decreases Immunity and Increases Susceptibility to Influenza Infection in Mice

Andrew K. Taylor; Weiping Cao; Keyur P. Vora; Juan A. De La Cruz; Wun-Ju Shieh; Sherif R. Zaki; Jacqueline M. Katz; Suryaprakash Sambhara; Shivaprakash Gangappa

BACKGROUNDnProtein energy malnutrition (PEM), a common cause of secondary immune deficiency in children, is associated with an increased risk of infections. Very few studies have addressed the relevance of PEM as a risk factor for influenza.nnnMETHODSnWe investigated the influence of PEM on susceptibility to, and immune responses following, influenza virus infection using isocaloric diets providing either adequate protein (AP; 18%) or very low protein (VLP; 2%) in a mouse model.nnnRESULTSnWe found that mice maintained on the VLP diet, when compared to mice fed with the AP diet, exhibited more severe disease following influenza infection based on virus persistence, trafficking of inflammatory cell types to the lung tissue, and virus-induced mortality. Furthermore, groups of mice maintained on the VLP diet showed significantly lower virus-specific antibody response and a reduction in influenza nuclear protein-specific CD8(+) T cells compared with mice fed on the AP diet. Importantly, switching diets for the group maintained on the VLP diet to the AP diet improved virus clearance, as well as protective immunity to viral challenge.nnnCONCLUSIONSnOur results highlight the impact of protein energy on immunity to influenza infection and suggest that balanced protein energy replenishment may be one strategy to boost immunity against influenza viral infections.


Journal of Immunology | 2012

Rapid Differentiation of Monocytes into Type I IFN-Producing Myeloid Dendritic Cells as an Antiviral Strategy against Influenza Virus Infection

Weiping Cao; Andrew K. Taylor; Renata Biber; William G. Davis; Jin Hyang Kim; Adrian J. Reber; Tatiana Chirkova; Juan A. De La Cruz; Aseem Pandey; Priya Ranjan; Jacqueline M. Katz; Shivaprakash Gangappa; Suryaprakash Sambhara

Myeloid dendritic cells (mDCs) have long been thought to function as classical APCs for T cell responses. However, we demonstrate that influenza viruses induce rapid differentiation of human monocytes into mDCs. Unlike the classic mDCs, the virus-induced mDCs failed to upregulate DC maturation markers and were unable to induce allogeneic lymphoproliferation. Virus-induced mDCs secreted little, if any, proinflammatory cytokines; however, they secreted a substantial amount of chemoattractants for monocytes (MCP-1 and IP-10). Interestingly, the differentiated mDCs secreted type I IFN and upregulated the expression of IFN-stimulated genes (tetherin, IFITM3, and viperin), as well as cytosolic viral RNA sensors (RIG-I and MDA5). Additionally, culture supernatants from virus-induced mDCs suppressed the replication of virus in vitro. Furthermore, depletion of monocytes in a mouse model of influenza infection caused significant reduction of lung mDC numbers, as well as type I IFN production in the lung. Consequently, increased lung virus titer and higher mortality were observed. Taken together, our results demonstrate that the host responds to influenza virus infection by initiating rapid differentiation of circulating monocytes into IFN-producing mDCs, which contribute to innate antiviral immune responses.


Journal of Virology | 2014

Activation of the RIG-I Pathway during Influenza Vaccination Enhances the Germinal Center Reaction, Promotes T Follicular Helper Cell Induction, and Provides a Dose-Sparing Effect and Protective Immunity

Raveendra R. Kulkarni; Mohammed Ata Ur Rasheed; Siddhartha Kumar Bhaumik; Priya Ranjan; Weiping Cao; Carl W. Davis; Krishna Marisetti; Sunil Thomas; Shivaprakash Gangappa; Suryaprakash Sambhara; Kaja Murali-Krishna

ABSTRACT Pattern recognition receptors (PRR) sense certain molecular patterns uniquely expressed by pathogens. Retinoic-acid-inducible gene I (RIG-I) is a cytosolic PRR that senses viral nucleic acids and induces innate immune activation and secretion of type I interferons (IFNs). Here, using influenza vaccine antigens, we investigated the consequences of activating the RIG-I pathway for antigen-specific adaptive immune responses. We found that mice immunized with influenza vaccine antigens coadministered with 5′ppp-double-stranded RNA (dsRNA), a RIG-I ligand, developed robust levels of hemagglutination-inhibiting antibodies, enhanced germinal center reaction, and T follicular helper cell responses. In addition, RIG-I activation enhanced antibody affinity maturation and plasma cell responses in the draining lymph nodes, spleen, and bone marrow and conferred protective immunity against virus challenge. Importantly, activation of the RIG-I pathway was able to reduce the antigen requirement by 10- to 100-fold in inducing optimal influenza-specific cellular and humoral responses, including protective immunity. The effects induced by 5′ppp-dsRNA were significantly dependent on type I IFN and IPS-1 (an adapter protein downstream of the RIG-I pathway) signaling but were independent of the MyD88- and TLR3-mediated pathways. Our results show that activation of the RIG-I-like receptor pathway programs the innate immunity to achieve qualitatively and quantitatively enhanced protective cellular adaptive immune responses even at low antigen doses, and this indicates the potential utility of RIG-I ligands as molecular adjuvants for viral vaccines. IMPORTANCE The recently discovered RNA helicase family of RIG-I-like receptors (RLRs) is a critical component of host defense mechanisms responsible for detecting viruses and triggering innate antiviral cytokines that help control viral replication and dissemination. In this study, we show that the RLR pathway can be effectively exploited to enhance adaptive immunity and protective immune memory against viral infection. Our results show that activation of the RIG-I pathway along with influenza vaccination programs the innate immunity to induce qualitatively and quantitatively superior protective adaptive immunity against pandemic influenza viruses. More importantly, RIG-I activation at the time of vaccination allows induction of robust adaptive responses even at low vaccine antigen doses. These results highlight the potential utility of exploiting the RIG-I pathway to enhance viral-vaccine-specific immunity and have broader implications for designing better vaccines in general.


Scientific Reports | 2017

Influenza virus exploits tunneling nanotubes for cell-to-cell spread.

Amrita Kumar; Jin Hyang Kim; Priya Ranjan; Maureen G. Metcalfe; Weiping Cao; Margarita Mishina; Shivaprakash Gangappa; Zhu Guo; Edward S. Boyden; Sherif R. Zaki; Ian A. York; Adolfo García-Sastre; Michael Shaw; Suryaprakash Sambhara

Tunneling nanotubes (TNTs) represent a novel route of intercellular communication. While previous work has shown that TNTs facilitate the exchange of viral or prion proteins from infected to naïve cells, it is not clear whether the viral genome is also transferred via this mechanism and further, whether transfer via this route can result in productive replication of the infectious agents in the recipient cell. Here we present evidence that lung epithelial cells are connected by TNTs, and in spite of the presence of neutralizing antibodies and an antiviral agent, Oseltamivir, influenza virus can exploit these networks to transfer viral proteins and genome from the infected to naïve cell, resulting in productive viral replication in the naïve cells. These observations indicate that influenza viruses can spread using these intercellular networks that connect epithelial cells, evading immune and antiviral defenses and provide an explanation for the incidence of influenza infections even in influenza-immune individuals and vaccine failures.


Expert Review of Vaccines | 2011

Improving immunogenicity and effectiveness of influenza vaccine in older adults

Weiping Cao; Jin Hyang Kim; Tatiana Chirkova; Adrian J. Reber; Renata Biber; David K. Shay; Suryaprakash Sambhara

Aging is associated with a decline in immune function (immunosenescence) that leads to progressive deterioration in both innate and adaptive immune functions. These changes contribute to the subsequent increased risk for infectious diseases and their sequelae. Vaccination is the most effective and inexpensive public health strategy for prevention of infection, despite the decreased efficacy of vaccines in older adults due to immunosenescence. The rapid rise in the older adult population globally represents a great challenge for vaccination programs. This article first addresses the status of innate and adaptive immune functions in aging and then focuses on influenza vaccine. The development history of influenza vaccines, current status, and potential strategies to improve the immunogenicity and vaccine effectiveness in older adults are discussed.


European Journal of Immunology | 2015

NLRC5 interacts with RIG‐I to induce a robust antiviral response against influenza virus infection

Priya Ranjan; Neetu Singh; Amrita Kumar; Andreas Neerincx; Elisabeth Kremmer; Weiping Cao; William G. Davis; Jacqueline M. Katz; Shivaprakash Gangappa; Rongtuan Lin; Thomas A. Kufer; Suryaprakash Sambhara

The NLR protein, NLRC5 is an important regulator of MHC class I gene expression, however, the role of NLRC5 in other innate immune responses is less well defined. In the present study, we report that NLRC5 binds RIG‐I and that this interaction is critical for robust antiviral responses against influenza virus. Overexpression of NLRC5 in the human lung epithelial cell line, A549, and normal human bronchial epithelial cells resulted in impaired replication of influenza virus A/Puerto Rico/8/34 virus (PR8) and enhanced IFN‐β expression. Influenza virus leads to induction of IFN‐β that drives RIG‐I and NLRC5 expression in host cells. Our results suggest that NLRC5 extends and stabilizes influenza virus induced RIG‐I expression and delays expression of the viral inhibitor protein NS1. We show that NS1 binds to NLRC5 to suppress its function. Interaction domain mapping revealed that NLRC5 interacts with RIG‐I via its N‐terminal death domain and that NLRC5 enhanced antiviral activity in an leucine‐rich repeat domain independent manner. Taken together, our findings identify a novel role for NLRC5 in RIG‐I‐mediated antiviral host responses against influenza virus infection, distinguished from the role of NLRC5 in MHC class I gene regulation.


Open Forum Infectious Diseases | 2015

Preexisting Immunity, More Than Aging, Influences Influenza Vaccine Responses

Adrian J. Reber; Jin Hyang Kim; Renata Biber; H. Keipp Talbot; Laura A. Coleman; Tatiana Chirkova; F. Liaini Gross; Evelene Steward-Clark; Weiping Cao; Stacie Jefferson; Vic Veguilla; Eric Gillis; Jennifer K. Meece; Yaohui Bai; Heather Tatum; Kathy Hancock; James Stevens; Sarah Spencer; Jufu Chen; Paul Gargiullo; Elise Braun; Marie R. Griffin; Maria E. Sundaram; Edward A. Belongia; David K. Shay; Jacqueline M. Katz; Suryaprakash Sambhara

Background.u2003Influenza disproportionately impacts older adults while current vaccines have reduced effectiveness in the older population. Methods.u2003We conducted a comprehensive evaluation of cellular and humoral immune responses of adults aged 50 years and older to the 2008–2009 seasonal trivalent inactivated influenza vaccine and assessed factors influencing vaccine response. Results.u2003Vaccination increased hemagglutination inhibition and neutralizing antibody; however, 66.3% of subjects did not reach hemagglutination inhibition titers ≥ 40 for H1N1, compared with 22.5% for H3N2. Increasing age had a minor negative impact on antibody responses, whereas prevaccination titers were the best predictors of postvaccination antibody levels. Preexisting memory B cells declined with age, especially for H3N2. However, older adults still demonstrated a significant increase in antigen-specific IgG+ and IgA+ memory B cells postvaccination. Despite reduced frequency of preexisting memory B cells associated with advanced age, fold-rise in memory B cell frequency in subjects 60+ was comparable to subjects age 50–59. Conclusions.u2003Older adults mounted statistically significant humoral and cell-mediated immune responses, but many failed to reach hemagglutination inhibition titers ≥40, especially for H1N1. Although age had a modest negative effect on vaccine responses, prevaccination titers were the best predictor of postvaccination antibody levels, irrespective of age.


Vaccine | 2016

A highly immunogenic vaccine against A/H7N9 influenza virus.

Weiping Cao; Justine S. Liepkalns; Ahmed O. Hassan; Ram P. Kamal; Amelia R. Hofstetter; Samuel Amoah; Jin Hyang Kim; Adrian J. Reber; James Stevens; Jacqueline M. Katz; Shivaprakash Gangappa; Ian A. York; Suryaprakash Sambhara

Since the first case of human infection in March 2013, continued reports of H7N9 cases highlight a potential pandemic threat. Highly immunogenic vaccines to this virus are urgently needed to protect vulnerable populations who lack protective immunity. In this study, an egg- and adjuvant-independent adenoviral vector-based, hemagglutinin H7 subtype influenza vaccine (HAd-H7HA) demonstrated enhanced cell-mediated immunity as well as serum antibody responses in a mouse model. Most importantly, this vaccine provided complete protection against homologous A/H7N9 viral challenge suggesting its potential utility as a pandemic vaccine.


Vaccine | 2016

High-dose influenza vaccine favors acute plasmablast responses rather than long-term cellular responses.

Jin Hyang Kim; H. Keipp Talbot; Margarita Mishina; Yuwei Zhu; Jufu Chen; Weiping Cao; Adrian J. Reber; Marie R. Griffin; David K. Shay; Sarah Spencer; Suryaprakash Sambhara

UNLABELLEDnHigh-dose (HD) influenza vaccine shows improved relative efficacy against influenza disease compared to standard-dose (SD) vaccine in individuals ⩾65years. This has been partially credited to superior serological responses, but a comprehensive understanding of cell-mediated immunity (CMI) of HD vaccine remains lacking. In the current study, a total of 105 participants were randomly administered HD or SD vaccine and were evaluated for serological responses. Subsets of the group (n=12-26 per group) were evaluated for B and T cell responses at days 0, 7, 14 and 28 post-vaccination by flow cytometry or ELISPOT assay. HD vaccine elicited significantly higher hemagglutination inhibition (HI) titers than SD vaccine at d28, but comparable titers at d365 post-vaccination. HD vaccine also elicited higher vaccine-specific plasmablast responses at d7 post-vaccination than SD vaccine. However, long-lived memory B cell induction, cytokine-secreting T cell responses and persistence of serological memory were comparable regardless of vaccine dose. More strategies other than increased Ag amount may be needed to improve CMI in older adults.nnnTRIAL REGISTRATIONnClinicalTrials.gov NCT 01189123.


Cellular Immunology | 2016

RIG-I ligand enhances the immunogenicity of recombinant H7HA protein

Weiping Cao; Justine S. Liepkalns; Ram P. Kamal; Adrian J. Reber; Jin Hyang Kim; Amelia R. Hofstetter; Samuel Amoah; James Stevens; Priya Ranjan; Shivaprakash Gangappa; Ian A. York; Suryaprakash Sambhara

Avian H7N9 influenza virus infection with fatal outcomes continues to pose a pandemic threat and highly immunogenic vaccines are urgently needed. In this report we show that baculovirus-derived recombinant H7 hemagglutinin protein, when delivered with RIG-I ligand, induced enhanced antibody and T cell responses and conferred protection against lethal challenge with a homologous H7N9 virus. These findings indicate the potential utility of RIG-I ligands as vaccine adjuvants to increase the immunogenicity of recombinant H7 hemagglutinin.

Collaboration


Dive into the Weiping Cao's collaboration.

Top Co-Authors

Avatar

Suryaprakash Sambhara

National Center for Immunization and Respiratory Diseases

View shared research outputs
Top Co-Authors

Avatar

Shivaprakash Gangappa

National Center for Immunization and Respiratory Diseases

View shared research outputs
Top Co-Authors

Avatar

Jin Hyang Kim

National Center for Immunization and Respiratory Diseases

View shared research outputs
Top Co-Authors

Avatar

Jacqueline M. Katz

National Center for Immunization and Respiratory Diseases

View shared research outputs
Top Co-Authors

Avatar

Adrian J. Reber

National Center for Immunization and Respiratory Diseases

View shared research outputs
Top Co-Authors

Avatar

Priya Ranjan

Oak Ridge National Laboratory

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ian A. York

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Juan A. De La Cruz

Battelle Memorial Institute

View shared research outputs
Top Co-Authors

Avatar

Renata Biber

National Center for Immunization and Respiratory Diseases

View shared research outputs
Researchain Logo
Decentralizing Knowledge